DexCom Valuation
| DXCM Stock | USD 73.36 0.31 0.42% |
At this time, the firm appears to be undervalued. DexCom Inc shows a prevailing Real Value of $76.97 per share. The current price of the firm is $73.36. Our model computes the value of DexCom Inc from reviewing the firm fundamentals such as Current Valuation of 27.99 B, shares outstanding of 390.02 M, and Profit Margin of 0.16 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting DexCom's valuation include:
Price Book 10.5398 | Enterprise Value | Enterprise Value Ebitda 22.8943 | Price Sales 6.3705 | Forward PE 29.6736 |
Undervalued
Today
Please note that DexCom's price fluctuation is very steady at this time. Calculation of the real value of DexCom Inc is based on 3 months time horizon. Increasing DexCom's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the DexCom stock is determined by what a typical buyer is willing to pay for full or partial control of DexCom Inc. Since DexCom is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DexCom Stock. However, DexCom's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 73.36 | Real 76.97 | Target 85.19 | Hype 72.88 | Naive 73.95 |
The intrinsic value of DexCom's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence DexCom's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of DexCom Inc helps investors to forecast how DexCom stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DexCom more accurately as focusing exclusively on DexCom's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use DexCom's intrinsic value based on its ongoing forecasts of DexCom's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against DexCom's closest peers.
DexCom Cash |
|
DexCom Total Value Analysis
DexCom Inc is currently forecasted to have valuation of 27.99 B with market capitalization of 28.77 B, debt of 2.59 B, and cash on hands of 2.37 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the DexCom fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
27.99 B | 28.77 B | 2.59 B | 2.37 B |
DexCom Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.03. DexCom Inc had not issued any dividends in recent years. The entity had 4:1 split on the 13th of June 2022. DexCom Inc is performing exceptionally good at this time. It has a great probability to report excellent financial results in March.DexCom Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. DexCom has an asset utilization ratio of 62.19 percent. This suggests that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that DexCom Inc is more efficient with each dollar of assets it utilizes for everyday operations.DexCom Profitability Analysis
Taking into consideration DexCom's profitability measurements, DexCom Inc is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in March. Profitability indicators assess DexCom's ability to earn profits and add value for shareholders.Net Income | First Reported 2003-12-31 | Previous Quarter 179.8 M | Current Value 283.8 M | Quarterly Volatility 75 M |
For DexCom profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DexCom Inc to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DexCom utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DexCom's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DexCom over time as well as its relative position and ranking within its peers.
DexCom Earnings per Share Projection vs Actual
By analyzing DexCom's earnings estimates, investors can diagnose different trends across DexCom's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for DexCom Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.DexCom Ownership Allocation
DexCom holds a total of 390.02 Million outstanding shares. The majority of DexCom Inc outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in DexCom Inc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in DexCom. Please pay attention to any change in the institutional holdings of DexCom Inc as this could imply that something significant has changed or is about to change at the company. On October 13, 2025, Representative Michael McCaul of US Congress acquired under $15k worth of DexCom Inc's common stock.DexCom Profitability Analysis
The company reported the previous year's revenue of 4.03 B. Net Income was 576.2 M with profit before overhead, payroll, taxes, and interest of 2.66 B.About DexCom Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of DexCom Inc. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of DexCom Inc based exclusively on its fundamental and basic technical indicators. By analyzing DexCom's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of DexCom's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of DexCom. We calculate exposure to DexCom's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DexCom's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.8 B | 2.9 B | |
| Pretax Profit Margin | 0.16 | 0.17 | |
| Operating Profit Margin | 0.13 | 0.14 | |
| Net Profit Margin | 0.13 | 0.14 | |
| Gross Profit Margin | 0.54 | 0.57 |
DexCom Growth Indicators
Investing in growth stocks can be very risky. If the company such as DexCom does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 412.7 M | |
| Quarterly Earnings Growth Y O Y | 1.099 | |
| Forward Price Earnings | 29.6736 |
DexCom Current Valuation Indicators
DexCom's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final DexCom's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as DexCom, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use DexCom's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes DexCom's worth.When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Will Health Care Equipment & Supplies sector continue expanding? Could DexCom diversify its offerings? Factors like these will boost the valuation of DexCom. Projected growth potential of DexCom fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DexCom data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.099 | Earnings Share 1.8 | Revenue Per Share | Quarterly Revenue Growth 0.216 | Return On Assets |
Understanding DexCom Inc requires distinguishing between market price and book value, where the latter reflects DexCom's accounting equity. The concept of intrinsic value—what DexCom's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push DexCom's price substantially above or below its fundamental value.
It's important to distinguish between DexCom's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DexCom should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, DexCom's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.